HK1211850A1 - Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy - Google Patents

Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy Download PDF

Info

Publication number
HK1211850A1
HK1211850A1 HK15112752.6A HK15112752A HK1211850A1 HK 1211850 A1 HK1211850 A1 HK 1211850A1 HK 15112752 A HK15112752 A HK 15112752A HK 1211850 A1 HK1211850 A1 HK 1211850A1
Authority
HK
Hong Kong
Prior art keywords
amino
pyrazolo
compound
ethyl
pyrimidine
Prior art date
Application number
HK15112752.6A
Other languages
English (en)
Chinese (zh)
Inventor
‧克萊林
V‧克莱林
‧蓋爾
J‧盖尔
‧塔米米
N‧塔米米
Original Assignee
辉瑞公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 辉瑞公司 filed Critical 辉瑞公司
Publication of HK1211850A1 publication Critical patent/HK1211850A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK15112752.6A 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy HK1211850A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717429P 2012-10-23 2012-10-23
US61/717,429 2012-10-23
PCT/IB2013/059239 WO2014064566A1 (en) 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy

Publications (1)

Publication Number Publication Date
HK1211850A1 true HK1211850A1 (en) 2016-06-03

Family

ID=49765599

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112752.6A HK1211850A1 (en) 2012-10-23 2013-10-09 Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy

Country Status (15)

Country Link
US (2) US20150274735A1 (https=)
EP (1) EP2911672A1 (https=)
JP (1) JP2015534977A (https=)
KR (1) KR20150056853A (https=)
CN (1) CN104755086A (https=)
AU (1) AU2013336293B2 (https=)
BR (1) BR112015008380A2 (https=)
CA (1) CA2888160A1 (https=)
HK (1) HK1211850A1 (https=)
IL (1) IL238374A0 (https=)
IN (1) IN2015DN03190A (https=)
MX (1) MX2015005004A (https=)
RU (1) RU2015115005A (https=)
SG (1) SG11201502286XA (https=)
WO (1) WO2014064566A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939328B1 (ko) * 2012-12-21 2019-01-16 주식회사 엘지화학 신규한 구조를 가지는 중공사막 및 그 제조 방법
EP3925957A4 (en) 2019-02-15 2022-11-02 Tohoku University 1,3-DIOXOLANE DERIVATIVE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
SI1881985T1 (sl) * 2005-05-12 2011-03-31 Pfizer Brezvodne kristalinične oblike N-1-(2-etoksietil)-5(N-etil-N-metilamino)-7-(4-metilpriridin-2-il-amino) -1H-pirazolo(4,3-d)pirimidin-3-karbonil"metansulfonamida
CA2608018C (en) * 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.

Also Published As

Publication number Publication date
CA2888160A1 (en) 2014-05-01
WO2014064566A1 (en) 2014-05-01
US20160136170A1 (en) 2016-05-19
AU2013336293A1 (en) 2015-04-09
JP2015534977A (ja) 2015-12-07
KR20150056853A (ko) 2015-05-27
MX2015005004A (es) 2015-07-17
SG11201502286XA (en) 2015-05-28
CN104755086A (zh) 2015-07-01
BR112015008380A2 (pt) 2017-07-04
IN2015DN03190A (https=) 2015-10-02
EP2911672A1 (en) 2015-09-02
AU2013336293B2 (en) 2016-05-12
US20150274735A1 (en) 2015-10-01
RU2015115005A (ru) 2016-12-20
IL238374A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
CN117105939B (zh) 稠合双环sGC刺激剂
EP3194395B1 (en) Sgc stimulators
EP3411026B1 (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
KR20230145446A (ko) Irak4 분해제 및 이의 용도
CA2534432A1 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
KR20090094090A (ko) 치료를 위한 방법 및 조성물
SG188238A1 (en) Combination therapy for treating hcv infection
CN111249282B (zh) 癌症疗法
TW200423932A (en) Combination of a PDE IV inhibitor and a TNF-alpha antagonist
HK1211850A1 (en) Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy
WO2010097501A2 (en) A combination treatment
US20100249103A1 (en) combination treatment
JP2006517557A (ja) 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンii拮抗薬と組み合わせたジピリダモールの使用
WO2010111905A1 (zh) 治疗2型糖尿病的药物组合物
AU2004216858B2 (en) Pyridylsulfonamido pyrimidines for treating diabetic nephropathy
CA2946151C (en) Stable solid immunosuppressor composition
WO2011027021A1 (en) A method for the treatment of hypertension
WO2018057933A1 (en) Compounds, compositions, and methods for reducing oxidative stress in cardiomyocytes
HK40001613B (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
TW201226411A (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings
HK1225030A1 (en) Sgc stimulators
HK1225030B (en) Sgc stimulators